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Primary and metastatic tumor growth induces host tissue responses that are believed to support tumor progression.
Understanding the molecular changes within the tumor microenvironment during tumor progression may therefore be
relevant not only for discovering potential therapeutic targets, but also for identifying putative molecular signatures that may
improve tumor classification and predict clinical outcome. To selectively address stromal gene expression changes during
cancer progression, we performed cDNA microarray analysis of laser-microdissected stromal cells derived from prostate
intraepithelial neoplasia (PIN) and invasive cancer in a multistage model of prostate carcinogenesis. Human orthologs of genes
identified in the stromal reaction to tumor progression in this mouse model were observed to be expressed in several human
cancers, and to cluster prostate and breast cancer patients into groups with statistically different clinical outcomes. Univariate
Cox analysis showed that overexpression of these genes is associated with shorter survival and recurrence-free periods. Taken
together, our observations provide evidence that the expression signature of the stromal response to tumor invasion in
a mouse tumor model can be used to probe human cancer, and to provide a powerful prognostic indicator for some of the
most frequent human malignancies.
Citation: Bacac M, Provero P, Mayran N, Stehle J-C, Fusco C, et al (2006) A Mouse Stromal Response to Tumor Invasion Predicts Prostate and Breast
Cancer Patient Survival. PLoS ONE 1(1): e32. doi:10.1371/journal.pone.0000032
INTRODUCTION
Malignant tumors are complex cellular ensembles composed, in
addition to tumor cells, of host tissue-derived fibroblasts,
endothelial cells, smooth muscle cells, and leukocytes. Despite
self-sufficiency in growth signal generation and resistance to
a variety of growth inhibitory and apoptosis-inducing stimuli,
tumor cells rely on support from the host tissue for survival, growth
and dissemination. In addition to constituting a reservoir of growth
factors, the host tissue stroma provides the means to generate
oxygen supply by supporting angiogenesis, as well as a structural
scaffold for tumor cell adherence and migration [1–4]. Tumor
cells must therefore possess the ability to exploit these resources to
their advantage.
Access to extracellular matrix (ECM)-sequestered growth
factors, initiation of angiogenesis and degradation of collagen
and various ECM glycoproteins that constitute a natural barrier to
invasion require the activation of a complex proteolytic enzyme
machinery that initiates and maintains ECM remodeling [5,6].
Numerous classes of extracellular proteinases are implicated in
ECM remodeling including serine, aspartyl and cysteine proteases,
members of the metzincin family, prominent among which are
matrix metalloproteinases (MMPs), and adamalysin related
proteinases [6–8]. Although some tumor cell types express a broad
range of proteolytic enzymes that allow them to induce ECM
remodeling by themselves, others lack the necessary proteolytic
arsenal and must rely on enzymes supplied by stromal cells [9,10].
By recruiting leukocytes, particularly macrophages, and by
activating fibroblasts through growth factor secretion and cell-cell
interaction, such tumor cells are believed to harness stromal cells
into secreting MMPs and other proteases that promote ECM
degradation and augment ECM-bound growth factor bioavail-
ability.
Thorough understanding of host responses to different types of
cancer growth, their prognostic significance and their potential
value as therapeutic targets has been hampered in part by the
approaches used to address them. Thus, tumor-host interactions
and their consequences have been studied mostly in tumor cell-
fibroblast co-culture systems and tumor xenograft models in
immunocompromised mice where the stromal microenvironment
may only partially reflect that of primary spontaneously arising
tumors [11,12]. Similarly, gene expression signatures of both
primary [13,14] and metastatic [15] tumors that may bear
prognostic significance and predict metastatic proclivity, respec-
tively, have for the most part been obtained from bulk tumor cell
populations, such that the relative contribution of the tumor and
stromal cell compartments could not be readily assessed.
To address the stromal response to tumor growth in a natural
setting, and to assess its potential prognostic relevance, we
examined the molecular events in the stromal cell compartment
during cancer progression in a transgenic mouse model of
multistage carcinogenesis. The choice of a mouse model rather
than human tissues was based on experience from numerous
studies that have highlighted the challenges associated with the use
of archival human tissues, both from technical and biological
viewpoints [16]. Variability as to sampling, tissue handling,
processing and storing can all play a major role in obscuring
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stromal responses to a given tumor may vary among patients
according to patient age and coexistence of disorders unrelated to
the malignancy. A well designed study to assess the stromal
response to a human tumor should therefore be prospective and
performed on a large number of individuals. While undoubtedly
valuable, such an approach requires substantial time and should
ideally be multicentric. Mouse tumor models, on the other hand,
provide uniformity based on a defined oncogenic mechanism that
drives tumor development, a unique genetic background and
reduced inter-individual variability. Highly reproducible assess-
ment of tumors at defined stages of evolution is therefore possible.
Furthermore, late stage tumors free of therapeutic intervention are
readily accessible in mouse models, in contrast to the correspond-
ing patient tissues that are typically obtained following chemo- or
radiation therapy.
The reproducibility of tumor development and progression in
mouse models predicts reproducibility of the corresponding host
tissue response and suggests that small numbers of animals may
suffice to allow identification of relevant stromal response gene
expression signatures. Such putative gene expression signatures
can then be used to probe human cancers and the functional
implication of the signature component genes in the disease
process can be tested.
The neuroendocrine prostate tumors that arise in the mouse
model used in the present study (CR2-TAg mice) have been
previously characterized and shown to reproduce the stages of
human tumor progression and metastasis [17,18]. Microarray
analysis of the stromal response to progression from intraepithelial
to invasive tumors revealed a gene expression set consistent with
ECM remodeling, characterized by the robust induction of genes
encoding ECM proteins, growth factors, adhesion receptors and
proteases. Remarkably, the gene expression set was found to
have a powerful prognostic value in human prostate and breast
cancer.
RESULTS
Laser capture microdissection
Neuroendocrine prostate tumors that arise in CR2-TAg mice and
evolve through a series of stages closely mimicking those observed
in human prostate cancer have been previously described [17,18].
Briefly, the mice are born with a normal prostate and develop
prostate intraepithelial neoplasia (PIN) by 8 weeks, which progress
to invasive carcinoma by 16–20 weeks, forming liver, lung, bone
and lymph node metastasis by 24 weeks of age. The invasive stage
is accompanied by a robust, predominantly fibroblastic, stromal
reaction rendering the model attractive for addressing host tissue
responses to invasive tumor growth. In the present study, prostates
bearing early PIN lesions and invasive prostate tumors were
removed from 10- and 24-week old CR2-TAg mice, respectively,
at autopsy (Figure 1A, B). The choice of the 10 week time point
was dictated by the observation that early invasion may already be
present at 12 weeks [17]. By contrast, PIN lesions without
evidence of microscopic invasion were abundant at 10 weeks
whereas at 24 weeks, 100% of the mice displayed invasive cancer
growth along with metastatic lesions. Following histological
assessment of the tissues, the stromal compartment from both
PIN lesions and invasive prostate tumors was selectively removed
by LCM (Figure S1) and the RNA was extracted, amplified and
subjected to microarray analysis.
cDNA microarray analysis of microdissected stroma
A global gene expression profile of microdissected stroma was
obtained on prostate tissue from 10 mice (4 with PIN, and 6 with
invasive tumors). Gene expression analysis revealed 396 transcripts
with differential expression between the two tumor stages (with
a false discovery rate (FDR) of 15%). Among these, 256 displayed
higher and 140 lower expression in invasive cancer stroma than in
PIN-associated stroma (Table S1). Functional gene ontology (GO)
annotation analysis revealed that one of the most significantly over
represented gene families in the invasive tumor stroma was
annotated to the term endopeptidase activity and contained transcripts
encoding proteolytic enzymes, including lysosomal proteases,
asparaginyl endopeptidases, matrix metalloproteinases and pro-
protein convertases (Table S2). Genes within this functional family
that may be relevant to tumor progression encode cathepsins B, C,
D, Z, legumain, a disintegrin-like and metalloprotease reprolysin
type with thrombospondin type 1 motif 4 (ADAMTS4), matrix
metalloproteinases 2 and 3 (MMP2, MMP3), and FURIN, which
processes latent precursor proteins into their biologically active
counterparts (Table 1).
Several of the other differentially expressed genes within the
reactive stroma, annotated to the term extracellular region, were also
candidate participants in the regulation of tumor growth and
invasion. Thus, increased expression of genes encoding structural
matrix components including, biglycan, procollagen type III, and
IV, cartilage associated protein, regulators of insulin growth-factor
bioavailability (IGFBP3), urokinase plasminogen activator re-
ceptor (PLAUR) and growth factor receptors (PDGFRB), may
all play essential parts in the control of mesenchymal cell growth
Figure 1. Histological appearance of PIN and invasive CR2-TAg prostate cancer lesions. (A) prostate glands of a 10-week old CR2-TAg mouse
showing flat and tufted patterns of PIN (arrowhead and arrow, respectively), and a paucicellular stroma (S); (B) invasive cancer lesion from a 24-week
old mouse where PIN acini have been replaced by solid tumor (T) and an abundant cellular, reactive stroma (S) composed primarily of fibroblasts/
myofibroblasts as assessed by vimentin/actin smooth muscle staining (data not shown). Tissue sections were stained using anti-SV40 antibody
(brown) and counterstained with haematoxylin. Magnification 1006.
doi:10.1371/journal.pone.0000032.g001
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(Table 1).
Validation of microarray results
A subset of differentially expressed genes were validated by
quantitative real-time RT-PCR on RNA extracted from micro-
dissected PIN and invasive tumor stroma derived from animals
that had not been used for microarray analysis. Genes selected for
validation encode proteins implicated in proteolysis (matrix
metalloproteinase 3 (MMP3), cathepsin C (CTSC), cathepsin D
(CTSD), and legumain (LGMN)), modulation of insulin-like
growth factor-1 bioavailability (IGFBP3), regulation of tumor
and stromal cell growth, including platelet-derived growth factor
receptor beta (PDGFRB), growth factor receptor bound protein 14
(GRB14), tumor protein D52-like 1 (TPD52L1) and PTEN-
induced kinase 1 (PINK1), cell cycle regulation (pituitary tumor
transforming gene, PTTG1), and survival (baculoviral IAP repeat-
containing 5, BIRC5, Figure 2A). Consistent with the microarray
data, MMP3, PDGFRB, CTSD, BIRC5, CTSC, PTTG1, IGFBP3,
and LGMN were found to display, respectively, 6-, 6-, 7-, 8-, 14-,
18-, 19- and 19-fold higher expression in the invasive cancer
stroma than in PIN stroma. In further support of the microarray
data, GRB14, TPD52L1 and PINK1 displayed 4-, 4-, and 5- fold
lower expression in invasive cancer than in PIN stroma (Figure 2A).
Immunohistochemical analysis confirmed that expression of
cathepsins D, B and Z was almost exclusively localised in the
stroma of invasive tumors (Figure 2B, E and S2A, B) but was
Table 1. Selected genes found to be induced in invasive-cancer stroma when compared to PIN stroma.
..................................................................................................................................................
UniGene Gene symbol Gene description
M P value
Endopeptidase activity (GO:0004175)
Mm.236553 Ctsb cathepsin B 1.9 2.3E-04
Mm.180056 Ctsc cathepsin C 2.5 2.4E-04
Mm.29564 Mmp2 matrix metalloproteinase 2 2.4 3.4E-04
Mm.271709 Ctsz cathepsin Z 1.5 4.2E-04
Mm.17185 Lgmn legumain 2.4 8.3E-04
Mm.2284 Hexa hexosaminidase A 1.9 9.5E-04
Mm.231395 Ctsd cathepsin D 1.8 9.9E-04
Mm.243921 Furin furin (paired basic amino acid cleaving enzyme) 0.5 1.1E-03
Mm.4993 Mmp3 matrix metalloproteinase 3 2.5 2.1E-03
Mm.23156 Adamts4 a disintegrin-like and metalloprotease (reprolysin type) with thrombosp. 1 motif, 4 2.2 2.1E-03
Mm.152941 Usp16 ubiquitin specific protease 16 0.9 2.1E-03
Mm.117112 Usp27x ubiquitin specific protease 27, X chromosome 0.7 3.0E-03
Extracellular region (selected genes) (GO:0005576)
Mm.249555 Col3a1 procollagen, type III, alpha 1 2.5 1.0E-04
Mm.244263 Ccl4 chemokine (C-C motif) ligand 4 0.9 1.5E-04
Mm.7386 Mfap2 microfibrillar-associated protein 2 1.5 1.8E-04
Mm.41751 Esam1 endothelial cell-specific adhesion molecule 1.5 2.9E-04
Mm.4146 Pdgfrb platelet derived growth factor receptor, beta polypeptide 1.1 3.2E-04
Mm.1359 Plaur urokinase plasminogen activator receptor 1 6.4E-04
Mm.24208 Il13ra1 interleukin 13 receptor, alpha 1 1.5 1.0E-03
Mm.2608 Bgn biglycan 2.1 1.1E-03
Mm.738 Col4a1 procollagen, type IV, alpha 1 1.5 1.1E-03
Mm.220821 Stab1 stabilin 1 2.4 1.5E-03
Mm.29254 Igfbp3 insulin-like growth factor binding protein 3 3 1.7E-03
Mm.276652 Pecam platelet/endothelial cell adhesion molecule 1.8 1.9E-03
Mm.21767 Cdh5 cadherin 5 1.7 2.0E-03
Mm.292711 Cx3cl1 chemokine (C-X3-C motif) ligand 1 1.4 2.3E-03
Mm.2271 Ccl9 chemokine (C-C motif) ligand 9 3.2 2.4E-03
Mm.20904 Crtap cartilage associated protein 1.5 2.4E-03
Mm.2044 Serpinf1 serine (or cysteine) proteinase inhibitor, clade F), member 1 1.9 2.5E-03
Mm.33582 Plxna2 plexin A2 1.1 2.7E-03
Two representative functional families are shown: Endopeptidase activity (GO:0004175), (all 12 overexpressed genes annotated to this family are shown), and
Extracellular region (GO:0005576), (18 representative genes selected for their biological relevance are shown). M is the difference between the average logarithmic
expression level for invasive cancer stroma (6 samples), and the average logarithmic expression level for PIN stroma (4 samples, used as the common reference). The
logarithmic expression level is defined as the log2 of the expression ratio between each sample and the common reference. P is the P-value of the two-tailed t-test.
When a gene is represented by more than one clone, M and P refer to the statistically most significant one.
doi:10.1371/journal.pone.0000032.t001
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e32absent from PIN stroma (Figure S2C, arrowheads). Anti-vimentin
antibody (Figure 2C), double anti-cathepsin D/anti-vimentin
antibody (Figure 2D), and double anti-cathepsin D/anti-actin
smooth-muscle antibody (data not shown) staining suggested that
cathepsins were expressed predominantly by fibroblasts and
myofibroblasts. Anti-SV40 antibody, which stained tumor cells
only, and anti-cathepsin antibody staining patterns were mutually
exclusive, indicating that cathepsin-positive cells within the stroma
were not tumor cells that had detached and migrated away from
the primary mass (Figure 2E–G). Western blot analysis of lysates
from cultured fibroblasts obtained from prostates bearing PIN
lesions and invasive cancer further confirmed the induction of
cathepsins B, D and Z in invasive tumor-derived fibroblasts even
after several days of culture (Figure 2H).
Cross-species gene-expression comparison provides
evidence that human orthologs of genes induced in
the stroma of invasive CR-2TAg tumors predict
prostate cancer patient survival
The gene expression profile of invasive tumor-associated stroma in
the CR2-TAg mouse model is consistent with tissue remodeling
and may conceivably reflect host tissue stromal response to some
Figure 2. Validation of stromal genes identified by microarray analysis. (A) Quantitative real-time RT-PCR confirmed microarray results for 11
transcripts found to be differentially expressed between PIN and invasive cancer stroma. For a better representation, genes induced in the invasive
cancer stroma were calibrated on the PIN stroma, those induced in the PIN stroma were calibrated on the invasive-cancer stroma. (B–G)
Immunohistochemical validation of cathepsin D expression in invasive cancer stroma; cathepsin D (brown) was highly expressed in stromal cells
(arrowheads) associated with invasive cancer, in contrast to tumor cells (T) where only occasional staining was seen (B,E); cells expressing cathepsin D
were positive for vimentin (brown), confirming their mesenchymal origin (C); double staining of cathepsin D (brown) and vimentin (blue) highlighted
their co-expression by fibroblasts/myofibroblasts (D); anti-SV40T antibody staining (nuclear, brown), (F), and double anti-cathepsin D/anti-SV40T
antibody staining (blue/brown, respectively), (G), further confirmed that cathepsin D expression was primarily in stromal cells. Nuclei were
counterstained with haematoxylin (B, C, E, F). Magnification 1006(B–D), 2006(E, G). (h) Western blot analysis confirmed increased expression of
cathepsin D, B and Z in fibroblasts derived from CR2-TAg prostate cancers (1) compared to those derived from PIN prostates (2). Samples were
collected from 24-week (invasive cancer) and 10-week old (PIN) mice, just as for the microarray experiments.
doi:10.1371/journal.pone.0000032.g002
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whether the mouse stromal genes identified herein are expressed in
human prostate cancers and to test their potential relevance for
patient survival, we developed a list of human orthologs of the
mouse genes found to be differentially expressed between PIN-
and invasive-cancer stroma. The genes within the list were
subdivided into those that were upregulated (labeled ‘‘stroma up’’
genes) and those that were downregulated (labeled ‘‘stroma down’’
genes) in the invasive-cancer stroma (Table S3). A previously
published data set of prostate cancer patients [13] for whom both
gene expression and disease recurrence data were obtained was
then analyzed for expression of the two groups of genes.
Unsupervised hierarchical clustering was used to divide patients
into two groups based only on the expression profiles of the genes
in our lists. Standard statistical methods were used to determine (a)
whether the two groups of patients thus defined showed
statistically significant differences in terms of survival/recur-
rence-free time (Kaplan-Meier analysis), and (b) whether the
genes within our lists had significantly higher predictive power
than randomly selected genes (univariate cox analysis).
Unsupervised hierarchical clustering of 79 prostate carcinoma
patients [13] based on ‘‘stroma up’’ genes resulted in two patient
groups (Figure 3A), with a significant difference in recurrence-free
time as assessed by Kaplan-Meier survival analysis (log-rank test
p=8.05610
25, Figure 3B). By contrast, groups of patients
obtained based on ‘‘stroma down’’ gene clustering did not differ
significantly in recurrence-free time (p=0.086, Figure S3A).
Cross-species gene-expression analysis therefore indicated that
genes found to be induced in the stroma in response to tumor
progression in CR2-TAg mouse model were not only expressed in
human prostate cancer but were able to predict patient outcome.
Survival-predictive ability of mouse stromal genes in
different human cancers
Given that a stromal reaction to tumor invasion not only occurs in
many cancer types but probably promotes tumor invasion and
metastasis, it is conceivable that at least some of the molecular
changes which occur in the tumor microenvironment during
tumor progression may be common to different cancer types. To
address this hypothesis we tested the applicability as a prognostic
indicator of the stromal gene expression set identified in the CR2-
TAg mouse model to several human malignancies known to
induce a robust stromal reaction, including breast, lung and gastric
carcinoma. The gene expression set was also tested in renal cell
carcinoma, a tumor with a weak stromal response, where it was
not expected to have prognostic value.
Unsupervised hierarchical clustering of 295 early-stage breast
carcinoma patients [14] using the list of upregulated stromal genes
(‘‘stroma up’’) identified two groups of individuals (Figure 4A).
Kaplan-Meier survival analysis of the two groups indicated that
they were significantly different with respect to survival
(p=6.97610
25, Figure 4B). The same analysis performed with
respect to metastasis-free evolution instead of survival time showed
that the two groups also differed significantly in the overall
metastasis-free disease duration (p=0.0018, Figure 4C). Consis-
tent with our observations on prostate cancer, genes found to be
downregulated in the stroma (‘‘stroma down’’) clustered the
patients into groups that did not significantly differ in survival
(p=0.2, Figure S3B), or metastasis-free disease duration (p=0.72,
Figure S3C).
By contrast, when ‘‘stroma up’’ genes were used to cluster 86
primary lung adenocarcinomas (67 stage I and 19 stage III tumors)
[19], the groups obtained did not display a significant survival
difference (p=0.985, Figure 4D). The same was true for a cohort
of 90 primary gastric adenocarcinoma patients [20], (p=0.583,
Figure 4E). As expected, based on the paucity of the stromal
response, unsupervised hierarchical clustering of 177 primary
renal cell carcinoma patients [21], using ‘‘stroma up’’ genes failed
to yield groups of patients with significantly different survival
curves (p=0.513, Figure 4F).
Univariate cox analysis provides a list of genes
related to survival
Although unsupervised clustering and Kaplan-Meier analysis
revealed that the overall list of ‘‘stroma up’’ genes had high
prognostic value for prostate and breast cancer patients, it did not
Figure 3. Prognostic value of ‘‘stroma up’’ genes for human prostate cancer. (A) Unsupervised hierarchical clustering of prostate cancer patients
(columns) obtained using ‘‘stroma up’’ genes (rows). Red indicates high relative levels of gene expression and green represents low relative levels of
gene expression. Genes in the cluster are ordered according to decreasing z values (Table S4). ‘‘Stroma up’’ genes divide prostate cancer patients in
two main clusters (red and blue); (B) Kaplan-Meier survival analysis of the groups of patients defined by ‘‘stroma up’’ genes shows that the two
groups of patients differ significantly in the overall survival time (p=8.05610
25; red, poor prognosis group; blue, good prognosis group). Similar
analyses performed using ‘‘stroma down’’ genes can be found in Figure S3A.
doi:10.1371/journal.pone.0000032.g003
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survival. To address this issue, we performed univariate Cox
analysis of the correlation between the level of gene expression and
survival time. Such analysis produced, for each gene in our list, a z
value indicating the strength and sign of the correlation: positive
values of z.1.96 indicated that overexpression of the gene was
statistically associated with poor prognosis (p,0.05), while
negative values of z,21.96 were statistically indicative of good
prognosis (p,0.05), (Tables S4–8). In general, for prostate and
breast data sets, ‘‘stroma up’’ genes tended to have higher z values
when compared to all genes present in the chip, confirming that
overexpression of these genes was associated with poor patient
survival (schematically represented in Figure 5A, B).
A cross-list comparison of transcripts with statistically significant
z values (p,0.05) in prostate and breast data sets (Tables S4, S5)
identified 12 genes that were common to both lists. Among these
genes were transcripts that encode transcription factors (CBFB),
nuclear proteins that regulate nuclear import (KPNA2), proteins
implicated in the structural organisation of the nucleus (TMPO),
proteins involved in chromosome organization (PTTG1,
SMC4l1), and a protein associated with centrosome separation
(NUSAP1). Other genes whose overexpression was associated with
poor survival of breast and prostate cancer patients encode
regulators of differentiation (ROD1), protein kinases (MAPK4),
and regulators of cytoskeletal organisation (TMSB10, Figure 5C).
In addition to the 12 gene set, some of the ‘‘stroma up’’ genes
displayed a tumor-specific association with prognosis. Thus,
overexpression of genes including CX3CL1, FURIN and MTLG
was associated with poor prognosis in breast cancer patients but
a favourable outcome in prostate cancer patients. Similarly, high
expression of the cathepsin family of proteases (CTSC, CTSZ,
CTSB) was found to be indicative of poor prognosis in breast
cancer patients but appeared to have no significant predictive
value in prostate cancer patients. Univariate cox analysis thus
confirmed that overexpression of ‘‘stroma up’’ genes was
associated with poor patient outcome and allowed the identifica-
tion of 12 genes that have strong predictive value for survival of
prostate and breast cancer patients.
Expression of PTTG1 and CTSD in human cancers
Two genes from the ‘‘stroma up’’ list were selected for
immunohistochemical validation in human tumors, the primary
goal being to determine their localisation rather than a precise
Figure 4. Prognostic value of ‘‘stroma up’’ genes in different human tumors. (A) Unsupervised hierarchical clustering of breast cancer patients
(columns) obtained using ‘‘stroma up’’ genes (rows) ordered according to decreasing z values (Table S5). ‘‘Stroma up’’ genes divide breast cancer
patients in two main clusters (red and blue). Kaplan-Meier survival analysis of the groups of patients defined by ‘‘stroma up’’ genes shows that the
two groups of patients differ significantly in the (B) overall survival time (p=6.97610
25), and (C) metastasis-free time (p=0.0018). Similar analyses
performed using ‘‘stroma down’’ genes can be found in Figure S3B,C. (D–F) Kaplan-Meier survival analysis of lung (D), gastric (E), and renal cell
carcinoma patients (F) shows that groups of patients defined by ‘‘stroma up’’ genes do not differ significantly in the overall survival time (p.0.05).
Red, poor prognosis group; blue, good prognosis group.
doi:10.1371/journal.pone.0000032.g004
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selected because it displayed the strongest correlation with poor
outcome of both prostate and breast cancer patients. The
cathepsin D gene (CTSD) was selected because it was found to
be (together with other members of the cathepsin protease family)
one of the most strongly induced transcripts in the reactive stroma
of the CR2-TAg mouse model and because its stromal expression
has been associated with poor prognosis in breast cancer [22].
Securin and cathepsin D expression were assessed by immuno-
histochemistry in an independent set of 20 prostate, 47 breast, 20
lung, and 11 ovarian cancer samples. Weak perinuclear securin
expression was observed in occasional cells in normal prostate and
breast epithelium but not in the corresponding stroma (data not
shown). An increase in securin expression was observed in both
epithelial and stromal cell compartments of late-stage PIN lesions
and in breast carcinoma in situ (Figure 6A, C). A further increase in
staining intensity along with redistribution to both cytoplasm and
nucleus were observed in invasive cancer stages (Figure 6B, D),
with the highest levels of expression observed in metastatic breast
cancer lesions irrespective of location (data not shown). Elevated
expression of securin was observed in all malignancies tested,
including lung (Figure 6E) and ovarian cancer (Figure 6F).
Consistent with the microarray data, securin expression was
found to be increased in the stroma of all tumors analyzed
compared to normal tissue stroma. Stromal fibroblasts and tumor-
infiltrating leukocytes were among the stromal cells that expressed
securin (Figure 6A–F, arrowheads).
Cathepsin D expression was observed in both epithelial and
stromal cells of prostate and breast tumors (Figures 7A, B),
whereas normal tissues were largely devoid of anti-cathepsin D
antibody staining (data not shown). Large cell lung carcinomas
and lung adenocarcinomas displayed predominantly tumor-cell
cathepsin D expression and weak stromal expression (Figure 7C,
D). Remarkably, small cell lung carcinoma (SCLC) and large cell
neuroendocrine lung carcinoma (LCNEC) displayed distinctive
cathepsin D expression that was limited to the stromal cell
compartment with little or no tumor cell staining (Figure 7E, F).
This expression pattern was highly reminiscent of the one
observed in the CR2-TAg mouse model.
Stromal cathepsin D expression may influence
tumor cell migration and proliferation
Given that stromal cathepsin D expression is observed in a broad
spectrum of tumors, we addressed its possible functional implica-
tions on tumor cell behavior. We first assessed migration of
prostate neuroendocrine tumor cells derived form CR2-TAg
mouse tumors (PNEC cells, [23]), in 3D matrigel co-cultures with
wt (CTSD
+/+) or cathepsin D-deficient (CTSD
2/2) fibroblasts.
PNEC cells displayed greater migration when co-cultured with
CTSD
+/+ than with CTSD
2/2 fibroblasts (Figure 8A). Similar
results were obtained using Boyden chamber assays where PNEC
cells migrated as a function of the conditioned culture media
derived from CTSD
+/+ or CTSD
2/2 fibroblasts used as the
chemoattractant (data not shown). In addition, treatment of PNEC
cells grown on plastic with conditioned media derived from
CTSD
+/+ fibroblasts resulted in increased proliferation (Figure 8B)
and a phenotypic change characterized by an elongated neuronal-
type morphology (Figure 8C). Conditioned culture medium from
CTSD
2/2 fibroblasts failed to induce these proliferative and
morphological changes (Figure 8B, D). However, conditioned
culture medium from CTSD2/2 fibroblasts transfected with wt
CTSD cDNA recapitulated the phenotypic changes of PNEC cells
induced by wt fibroblast-derived medium (data not shown),
suggesting that stromal cathepsin D expression may influence
neuroendocrine tumor cell proliferation and motility.
DISCUSSION
The present work has identified a cross-species relevant stromal
gene expression set in response to tumor invasion. Invasive CR2-
TAg cancer stroma displayed induction of genes encoding
numerous ECM proteins and ECM degrading enzymes, including
ADAMTS4, MMP2, MMP3 CTSB, CTSC, CTSD and PLAUR. The
combined substrate specificity of the induced proteolytic enzymes
Figure 5. Univariate cox analysis. Representative histograms of (A) prostate and (B) breast cancer data sets obtained using univariate cox analysis of
the correlation between the level of gene expression and survival time. Histograms show that the distribution of the z variable of ‘‘stroma up’’ genes
(purple) is significantly higher than that of all genes present in the chip (green); (C) selected genes obtained by cross-list comparison of Tables S4 and
S5 found to have strong predictive value for the survival of breast and prostate cancer patients. Only genes having a p value,0.05 in both tables
were selected. The z value (and sign) indicate the strength of the correlation between the expression level of a gene and patient survival: the larger
the positive value of z the greater the association of the overexpression of the corresponding gene with poor outcome.
doi:10.1371/journal.pone.0000032.g005
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fibronectin, fibrin, laminin and vitronectin, and latent growth
factors, including among others, hepatocyte growth factor (HGF),
TGF-b, and basic FGF [11],[24,25]. The gene expression profile
of stromal cells associated with tumor progression in CR2-TAg
mice is therefore consistent with ECM remodeling functions that
may be expected in a robust stromal reaction to processes ranging
from mechanical tissue injury to tumor growth.
Stromal reaction to invasive tumor growth is widely believed to
support tumor progression by providing growth factors, cytokines
and ECM components that promote tumor cell survival, pro-
liferation and migration [1],[3]. As such, at least some of the genes
implicated in orchestrating stromal responses to tumor invasion
should predict tumor evolution. Consistent with this notion, the
gene expression signature identified in the present study bears
a powerful prognostic value for human prostate and breast cancer,
both of which are associated with a robust stromal response.
However, its applicability to human cancers associated with
a stromal reaction was not universal and could not predict the
outcome of gastric and lung carcinoma. There are several possible
explanations for this observation. First, a stromal response and the
corresponding tissue remodeling are complex processes that
comprise a broad range of cellular and molecular events and that
may differ among tumor types, partly because of tumor
characteristics and partly because of variability in host tissue
properties from one organ to another. Thus, the stromal reaction
typically associated with prostate and particularly breast cancer is
rich in fibroblasts, myofibroblasts and ECM proteins, resembling
that observed in the CR2-TAg model. Cancers that generate
ulcerating lesions, such as gastric carcinoma, on the other hand,
may be expected to induce a stromal reaction with a more
prominent inflammatory component, characterized by an abun-
dant leukocytic infiltrate and angiogenesis. It appears likely that
these two types of stromal reaction display different gene
expression signatures, each one having potential prognostic
relevance to the type of cancer it is associated with. Second, the
use of different technical approaches, including different types of
microarrays containing non-identical gene sets relevant to the
stroma and corresponding annotations, may, at least in part
account for the apparent absence of signature consistency between
studies [16],[26]. Third, most human tumor profiling studies have
been conducted on bulk tumor tissue, such that it is impossible to
know the relative representation of the stromal component which
may vary significantly among samples, obscuring the emergence of
Figure 6. Histological pattern of securin expression in human cancers. Representative images of securin expression in human cancer samples.
Securin expression (brown) is observed in tumor and stromal (arrowheads) cells in (A) late-stage PIN and (C) breast carcinoma in situ tissue sections.
Invasive cancer stages of (B) prostate, (D) breast, (E) lung, and (F) ovarian cancers show strong securin expression by both tumor and stromal
(arrowheads) cells. Nuclei were counterstained with haematoxylin. Magnification 2006.
doi:10.1371/journal.pone.0000032.g006
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generate and compare gene expression profiles of host responses to
different tumor types using standardized technical approaches.
However, candidate stromal gene expression signatures that are
relevant to tumor progression may already emerge by comparing
results of studies such as ours to those that have addressed the
potential relevance to cancer of stromal cell gene expression profiles
in a variety of pathophysiological conditions, including proliferative
fibroblastic disorders and injury-associated tissue repair.
A recent study identified a set of genes whose expression pattern
distinguished two proliferative fibroblastic disorders from each
other, solitary fibrous tumors (SFT) and desmoid-type fibroma-
toses (DTF), and demonstrated that expression of this gene set was
able to define two groups of breast carcinoma patients that differed
significantly in overall survival [27]. Cross-study comparison
between our set of ‘‘stroma up’’ genes and the ‘‘DTF genes’’
revealed 15 common transcripts (Table S9). Among genes
common to the two signatures are several ECM components
and ECM degrading enzymes, including COL1A2, COL3A1,
BGN, MPAF2 and CTSC. By contrast, comparison to the ‘‘SFT
gene set’’ of the same study did not yield significant overlap, as was
the case for comparison of the ‘‘stroma down’’ genes to both the
DTF and SFT gene sets. These observations suggest that the
‘‘stroma up’’ genes are more likely to be found in DTFs, known to
be locally more aggressive and to have a higher degree of
recurrence than SFTs.
A study focusing on the gene expression program in cultured
primary fibroblasts in response to serum, believed to reflect the
functional role of fibroblasts in wound healing, found that the
‘‘wound-response signature’’ was coordinately regulated in many
human tumors and was a powerful predictor of the clinical course
in several carcinomas [28,29]. However, the overlap between the
gene sets of this study and ours was limited to 8 genes (Table S9).
This could be attributed, at least in part, to differences in
experimental design, since Chang et al. addressed the effect of
serum on in vitro cultured fibroblasts whereas we analyzed the
stromal reaction to tumor progression in vivo, which implicates the
contribution of several other components of the tumor microen-
vironment, including leukocyte infiltration, ECM deposition, and
angiogenesis.
A third study used serial analysis of gene expression (SAGE) to
assess the expression profiles of the epithelial and stromal cell
Figure 7. Histological pattern of cathepsin D expression in human cancers. Representative images of cathepsin D expression in human cancer
samples. (A) prostate (B) breast cancer showing cathepsin D expression (brown) by tumor and stromal cells; (C) large-cell lung carcinoma and (D) lung
adenocarcinoma showing cathepsin D expression by tumor cells and to a lesser extent by stromal cells; (E, F), cathepsin D is almost exclusively
expressed by stromal cells in small-cell lung carcinomas (E) and large-cell neuroendocrine carcinomas (F), whereas tumor cells are almost devoid of
cathepin D expression. Nuclei were counterstained with haematoxylin. Magnification 2006.
doi:10.1371/journal.pone.0000032.g007
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transcripts with the ones identified in the present work revealed
several genes that were shared between our study and their
‘‘myoepithelial cell, myofibroblasts’’ and ‘‘stroma’’ SAGE libraries,
including ADFP, ANXA1, BGN, CCL4, COL1A2, COL3A1,
CXCR4, LAPTM5, MMP2, MT2A, SERPINF1, TMSB10 and
TRA1 (Table S9).
It is noteworthy that two of the genes that were found to predict
poor survival of prostate and breast cancer patients in the present
study (PTTG1 and COL1A2), form part of a 17-gene signature
associated with metastases [15]. Expression of the PTTG1 gene
was among the most significant components within the prognostic
gene expression signature in prostate and breast carcinoma. Its
expression in the tumor cell compartment of prostate and breast
cancer samples and its increase with the degree of tumor
progression were consistent with its implication in tumor de-
velopment [31]. Surprisingly, whereas most studies have reported
its expression to be confined to the tumor cell compartment, we
observed securin expression in both the tumoral and stromal
compartments of invasive cancers. Elucidation of the role of
securin in the tumor stroma will be of interest. It is attractive to
speculate, for example, that securin-positive stromal cells reflect an
active state that may contribute to tumor progression.
Another unexpected observation of the present work was the
robust induction of cathepsins B, C, D and Z, in the invasive CR2-
TAg cancer stroma mimicking the almost exclusively stromal
cathepsin D expression pattern in human SCLC and LCNEC.
Cathepsins have recently been shown to be upregulated in
multistage pancreatic islet cell tumor model where they contrib-
uted to invasive tumor growth [32],[33]. They have also been
suggested to participate in the progression of a variety of human
cancers [34],[35] and their expression in breast cancer stroma has
been shown to correlate with poor prognosis [22]. These findings
are consistent with our present observations and reports by others
that cathepsin D has mitogenic properties in tumor cells and
fibroblasts [36]. Although the functional importance of stromal-
derived cathepsins in tumor progression has yet to be fully
elucidated, the stroma is known to provide MMP-mediated
proteolysis in a variety of tumor models and some human cancers
[9]. It is conceivable that in at least some tumor types cathepsins
may function in an analogous manner.
Recent work by others has shown that cancer genes identified in
mouse models can be used to probe human malignancies and to
identify genes implicated in human cancer development and
progression [37–40]. Our observations demonstrate the feasibility
of using a mouse tumor model to identify a stromal gene
expression set associated with tumor progression that is not only
present in human prostate and breast cancer but that can predict
the outcome of both malignancies. Several of the genes within the
set identified in the present study have been associated with poor
prognosis, recurrence and metastatic proclivity of several human
tumors and their precise role in promoting tumor progression can
now be assessed.
MATERIALS AND METHODS
Animals and sample collection
Mice hemizygous for the CR2-TAg transgene were maintained in
a specific pathogen-free facility according to Swiss guidelines for
animal experimentation (authorization #1477). Samples (PIN
prostates and prostate tumors) were collected from transgenic mice
(CR2-TAg) expressing simian virus 40 large T antigen (SV40 TAg)
in prostatic neuroendocrine cells under regulatory elements from
the cryptidin-2 gene (Defcr2), described earlier [17],[18]. For the
Figure 8. Stromal cathepsin D expression promotes PNEC cell migration and proliferation. (A) Quantification of PNEC cell migration in 3D matrigel
co-culture with cathepsin D-deficient (CTSD
2/2) or wild-type (CTSD
+/+) fibroblasts after 30h of co-culture; (B) PNEC cell proliferation and (C, D)
elongation are increased in the presence of conditioned medium (CM) derived from CTSD
+/+ fibroblasts (C), compared to CM derived from CTSD
2/2
fibroblasts (D). Experiments were performed three times, each time in quintuplicate. Representative results are shown. *p,0.05, ***p,0.001, Student
t test.
doi:10.1371/journal.pone.0000032.g008
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tumors with lung and liver metastases were collected from 10- and
24-week old mice, respectively. Tissues were isolated in RNase free
conditions, snap-frozen in liquid nitrogen and stored at 280uC
until use.
Laser capture microdissection
LCM slides of prostate tissue from 10- and 24-week old mice
bearing PIN lesions (n=4 mice) and invasive cancer (n=6 mice),
respectively, were prepared from serial 8-mm-thick frozen tissues
sections placed on a polyvinyl nuclease free membrane (Molecular
Machines&Industries, Glattbrugg, CH). Tissue sections were fixed
in ethanol 70% (30 sec), stained with haematoxylin and eosin
(15 sec each), dehydrated in graded ethanol, treated with xylene
and air-dried in a sterile laminar flow hood. Slides were
microdissected immediately following staining using a mCut Laser
Microdissection system (Nikon Eclipse TE200). All steps and
solutions were performed under RNase free conditions. Generally,
1000–5000 cells were microdissected for subsequent RNA
extraction. Microdissected stromal regions were within 0–
100 mm and 0–300 mm from the epithelial compartment in the
PIN and invasive-cancer tissue sections, respectively. All
samples were subjected to histological examination prior to
microdissection.
RNA extraction, amplification and microarray
analysis
Total RNA was extracted immediately following microdissection
using the PicoPure RNA isolation kit (Arcturus, Mountain View,
CA, www.arctur.com), according to the manufacturer’s instruc-
tions. RNA was quantified using NanoDrop spectrophotometer
(NanoDrop Technologies, Wilmington, Delaware, USA), and the
concentration ranged between 10–50 ng/sample. RNA quality
was assessed using the RNA 6000 Pico Assay Kit (Agilent). Only
good quality RNA was subjected to two rounds of linear
amplification using the RiboAmp
TM RNA Amplification kit
(Arcturus), according to the manufacturer’s instructions, and
aRNA was quantified using RNA 6000 Nano Assay Kit (Agilent).
Labeled cDNA was obtained by reverse transcription of 5 mgo f
aRNA and incorporation of Cy3-dCTP and Cy5-dCTP (Amer-
sham Biosciences, Amersham, UK). Microarrays containing
17,000 spotted cDNA clones were obtained from the Lausanne
DNA Array Facility (http://www.unil.ch/dafl) and expression
analysis performed using the NIA 17k clone set ([41] http://
intranet.isrec.isb-sib.ch/microarrays/arrays_users.html). Hybrid-
ization of labeled cDNA to microarrays was performed for 16 h
at 64uC in a humidified chamber (Corning Costar, Cambridge,
MA). Microarrays were imaged using the ScanArray 4000 scanner
(Perkin Elmer, Foster City, CA); Cy3 and Cy5 fluorescence
intensities were extracted using the ScanAlyze software (http://
rana.lbl.gov/EisenSoftware.htm). Gene expression was quantified
with the SMA package using print tip group lowess normalization
without background subtraction [42,43]. For each array and each
clone log2 ratios (M values) and the average log2 intensities (A
value) of Cy3 and Cy5 signals were thus obtained. Intensity values
produced by the image analysis software ScanAlyze as well as
normalized gene expression data for all slides are available at
GEO, accession number GSE5945.
Experimental design and statistical analysis
For the identification of differentially expressed genes between
stroma microdissected from the PIN- and invasive-cancer stages,
samples from 10 mice, 6 with invasive cancer and 4 with PIN,
were analyzed. The common reference (control) for all 10 samples
was provided by pooled mRNA from the 4 PIN samples. In each
of the 10 microarrays the control RNA (pooled from 4 PIN
samples) was labeled with Cy3 and the test RNA (derived from
each PIN lesion and invasive carcinoma) with Cy5. Log-ratios of
the mRNA abundance for each clone were analyzed with
a standard two-tailed, two-sample t-test to identify differentially
expressed clones. To control the rate of false positives while taking
into account the issue of multiple testing we used the Benjamini-
Hochberg [44] method to produce lists of differentially expressed
clones with a controlled false discovery rate (FDR).
Functional analysis of differentially expressed genes
The lists of differentially expressed clones obtained as described
above were analyzed from the point of view of functional
annotation by searching for statistically overrepresented Gene
Ontology (GO) annotations [45]. This analysis was performed
separately for induced and repressed clones. Since GO terms are
attributed to genes rather than to clones, the lists of differentially
expressed clones were first translated into lists of genes (identified
by Ensembl gene IDs [46]) using the Refseq ID, the gene symbols
reported for each clone in the annotation of the microarray, and
the correspondence between Refseq IDs, gene symbols and
Ensembl IDs given by the Ensmart tool for browsing Ensembl.
The lists of genes were in general shorter than the original lists of
clones both because multiple clones were associated with the same
gene and because clones that could not be associated with any
gene were present. Gene Ontology annotations for all the genes
associated with at least one clone spotted on the microarray were
downloaded using ENSMART [47]. We then tested the lists of
induced and repressed genes for overrepresentation of GO terms
by applying the exact Fisher’s test.
Survival analysis of publicly available data
Gene expression and survival data for a cohort of prostate cancer
patients was kindly provided by William Gerald [13]. Publicly
available gene expression data for cohorts of breast cancer [14],
lung cancer [19], gastric cancer [20], and renal cell carcinoma
(RCC) [21] patients were obtained on-line together with
corresponding survival data. When raw Affymetrix data were
available (prostate and lung cancer) we applied the RMA
algorithm {rma} to obtain gene expression data. In the other
cases (breast, gastric cancer and renal cell carcinoma) we used the
expression data provided by the authors. Unsupervised hierarchi-
cal clustering of the patients was performed using Pearson
correlation coefficient to define dissimilarity between patient
expression profiles, obtaining two clusters of patients in each case.
The statistical significance of differences in survival probability
between the two clusters was computed with the log-rank test.
Univariate Cox analysis was performed to determine significant
correlations between the expression profile of each individual gene
represented on the chips and survival time. These analyses were
performed using R {r} and the Bioconductor suite {biocond}.
Real-time quantitative reverse transcription-PCR
cDNA was obtained using an Moloney murine leukemia virus
reverse transcriptase and RNase H minus (Promega, Madison,
WI). 50 ng of template total RNA were used per reaction. Real-
time PCR amplification was done using a Taqman Universal PCR
mastermix in an ABI Prism 7700 instrument (Applied Biosystems,
Foster City, CA). Relative quantitation of target, normalized with
an endogenous control (18s rRNA and GAPDH) was done using
a comparative (Ct) method according to the manufacturer’s
Stromal Response to Tumors
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(Applied Biosystems) were commercially available for MMP3
(Mm00440295_m1), CTSD (Mm00515587_m1), CTSC
(Mm00515580_m1), IGFBP3 (Mm00515156_m1), eukaryotic
18S rRNA (Hs99999901_s1), and were designed using Primer
Design program (Applied Biosystems) for PTTG1, BIRC5,
PDGFRB, LGMN, GRB14, TPD52L1, PINK1. The sequences
of the forward and reverse primers are provided in the
supplemental materials and methods.
Cell lines and proliferation assay
Prostate neuroendocrine cancer cells (PNEC) were previously
described [23] and cultured in 75 cm
2 Costar flasks coated with
high molecular weight poly-L-lysine (0.1 mg/mL, P1274 Sigma),
and laminin (2 mg/cm
2, L2020, Sigma), in DMEM/F12 medium
(Sigma) supplemented with 10% FBS, 1% non-essential amino
acids (NEAA, Gibco), B27 serum supplement (17504-044,
Invitrogen), 5 ng/ml EGF (354001, BDBiosciences) and 5 ng/ml
bFGF (F5392, Sigma). Cathepsin D deficient (CTSD
2/2) and
wild-type fibroblasts (CTSD
+/+) [36] were cultured in DMEM
medium supplemented with 10% FBS and 1% NEAA. Condi-
tioned medium (CM) was prepared using 80% confluent
fibroblasts cultures in DMEM without FBS for 48 h. After
collection, the CM was centrifuged at 800 g for 10 min, aliquoted
and stored at 280uC if not immediately used.
For the proliferation assay, PNECs were trypsinized, counted
and plated in 96-well plates (Costar) at 15 000 cells/100 ml
medium/well. Medium was removed 24 h after plating, the cells
washed once with PBS and incubated with the corresponding
conditioned medium (100 ml/well) for 24–96 h. Cell proliferation
was assessed using BrdU Cell proliferation ELISA assay kit (cat. 11
647 229 001, Roche) according to the manufacturer’s instructions.
Absorbance was measured using an ELISA plate reader at 410 nm
with background subtraction at 492 nm.
Immunohistochemistry
Paraffin-embedded tissue sections (4-mm thick) were deparaffinized
and hydrated according to standard procedures. Endogenous
peroxidase was quenched with 1% hydrogen peroxide for 15 min.
Sections were subjected to antigen retrieval by boiling in citrate
buffer (10 mM, pH 6.0) or EDTA (1 mM, pH 7.5) for 15 min,
cooled, washed, and incubated with avidin/biotin blocking
solutions to quench the endogenous biotin. Frozen 4-mm thick
tissue sections were acetone-fixed and rehydrated prior to
immunostaining and blocked for non-specific binding with 1%
bovine serum albumin (Fluka). For single antibody staining,
individual sections were incubated with primary antibodies
(diluted as indicated below) for 40 min at room temperature
(anti-SV40 and anti-securin antibodies were incubated overnight
at 4uC). For double antibody staining, sections were incubated
with the two antibodies in two serial steps. Sections were then
processed using standard avidin–biotin immunohistochemical
techniques according to the manufacturer’s recommendations
(Vector Laboratories, Burlingame, CA). Diaminobenzidine (DAB)
was used as a chromogen for the single antibody staining, together
with 5-bromo-4-chloro-3-indolyl phosphatase (BCIP/NBT) or
Fast Blue for the double antibody staining.
The antibodies were purchased as follows: biotin conjugated
anti-mouse Cathepsin D (BAF1029, 50 mg/ml, dil.1:5), anti-mouse
Cathepsin B (AF965, 100 mg/ml, dil.1:10), and anti-Cathepsin X/
Z/P (AF1033, 100 mg/ml, dil.1:5), all from R&D Systems (San
Diego, CA, USA); biotin conjugated anti-SV40 large T, small T
antigen (cat. 554151, 0.1 mg, BD Pharmingen, dil. 1:20);
biotinylated anti-vimentin Ab-2 Clone V9 (MS-129-P1, 200 mg/
ml, Neo Markers, Lab Vision Corporation, USA, dil.1:50); anti-
actin smooth muscle (Abcam Ltd, Cambridge, UK, dil.1:50);
mouse anti human securin (PTTG1) (ab3305, 0.2 mg/ml, Abcam,
dil.1:50); ECL streptavidin-HRP (from Amersham Biosciences);
streptavidin-AP (Roche Applied Science); polyclonal rabbit anti-
goat immunoglobulins/HRP, goat anti-rabbit immunoglobulins
HRP, and BCIP/NBT substrate system (DakoCytomation); DAB
tablets and Fast Blue BB salt (Sigma). For routine histopathological
examination, 4-mm-thick frozen tissue sections were H&E stained
according to standard procedures.
SUPPORTING INFORMATION
Figure S1. Example of laser-microdissected stroma. Ex-
ample of laser-microdissected (LCM) stroma from tumor sections
derived from 24-week old animals. (A) H&E-stained tissue section
prior to LCM; (B) after LCM; (C) the remaining tissue section after
the dissected stroma had been removed; (D) the microdissected
stroma (measuring 300x1000mm). The sections were 8 mm thick,
magnification 200x.
Found at: doi:10.1371/journal.pone.0000032.s001 (1.69 MB TIF)
Figure S2. Immunohistochemical validation of cathepsin
expression in CR2-TAg tissue sections. Immunohistochem-
ical validation of (A) cathepsin B and (B) cathepsin Z expression
(brown) showing almost exclusive stromal cell expression on
sections derived from 24-week old CR2-TAg mice. Note that only
occasional tumor cells within the same sections are stained for
cathepsin B or Z; (C) cathepsin D (brown) is found to be expressed
by epithelial, but not by stromal cells (arrowheads), on PIN
sections derived from 10 week-old CR2-TAg mice. Nuclei were
counterstained with haematoxylin. Magnification 200x.
Found at: doi:10.1371/journal.pone.0000032.s002 (2.44 MB TIF)
Figure S3. "Stroma down" genes do not predict the survival
of prostate and breast cancer patients. Kaplan-Meier
survival analysis of (A) prostate and (B,C) breast cancer patients
using "stroma down" genes. Note that the two groups of patients
are not significantly different in the overall survival/recurrence-
free and metastasis-free time (p.0.05).
Found at: doi:10.1371/journal.pone.0000032 (0.19 MB TIF)
Table S1. Differentially expressed clones identified by
microarray analysis. List of differentially expressed clones
between stroma microdissected from PIN and invasive-prostate
cancers of CR2-TAg mice. The columns "M" and "STD M"
contain mean and standard deviations of the log2 value of the
expression ratio for the six invasive cancer samples; the next two
columns refer to the four PIN samples. A pool of the four PIN
samples was used as the reference for all 10 chips. The columns "t"
and "P-value" give the statistical and the P-value for the two-
sample, two-tailed t-test. M is the difference between the average
logarithmic expression level for invasive cancer stroma (6 samples),
and the average logarithmic expression level for PIN stroma (4
samples, used as the common reference). The logarithmic
expression level is defined as the log2 of the expression ratio
between each sample and the common reference.
Found at: doi:10.1371/journal.pone.0000032.s004 (0.11 MB
XLS)
Table S2. Functional Gene Ontology A list of ENSEMBL ids
associated with the clones listed in Table S1 was generated using
the ENSMART tool, which was also used to download the Gene
Ontology annotation terms associated with each gene. The
analysis was performed separately for "stroma up" and "stroma
down" genes. "Genome_occurrences" indicates the number of
Stromal Response to Tumors
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"set_size" indicates the number of differentially expressed genes;
"set_occurrences" indicates the number of genes annotated to the
GO term among the differentially expressed ones; "expected_oc-
currences" indicates the number expected by chance alone;
"p_value" indicates the P-value of Fisher’s exact test; "cutoff"
indicates the cutoff on such p-values derived from the simulation
and corresponding to a 95% confidence level.
Found at: doi:10.1371/journal.pone.0000032.s005 (0.09 MB XLS)
Table S3. Correspondence list between differentially ex-
pressed clones
Found at: doi:10.1371/journal.pone.0000032.s006 (0.10 MB XLS)
Table S4. Univariate cox analysis of clones used in the
prostate cancer study. List of clones obtained using univariate
cox analysis of "stroma up" and "stroma down" genes presented in
Table S3, mapped to the prostate cancer data set [13]. The
expression level of each gene was correlated with patient survival,
resulting in the z value that indicates the strength of the
correlation. Only genes having z values.1.96 or ,-1.96,
(p,0.05), were considered to be statistically significantly associated
with patient survival. Positive values of z.1.96 indicate that
overexpression of the gene is statistically associated with poor
prognosis while negative values of z,-1.96 are statistically
indicative of good prognosis. Genes are ordered according to
decreasing z values.
Found at: doi:10.1371/journal.pone.0000032.s007 (0.10 MB XLS)
Table S5. Univariate cox analysis of clones used in the
breast cancer study. List of clones obtained using univariate
cox analysis of "stroma up" and "stroma down" genes presented in
Table S3, mapped to the breast cancer data set [14].
Found at: doi:10.1371/journal.pone.0000032.s008 (0.08 MB XLS)
Table S6. Univariate cox analysis of clones used in the lung
cancer study. List of clones obtained using univariate cox
analysis of "stroma up" genes presented in Table S3, mapped to
the lung cancer data set [19].
Found at: doi:10.1371/journal.pone.0000032.s009 (0.05 MB XLS)
Table S7. Univariate cox analysis of clones used in the
gastric cancer study. List of clones obtained using univariate
cox analysis of "stroma up" genes presented in Table S3, mapped
to the gastric cancer data set [20].
Found at: doi:10.1371/journal.pone.0000032.s010 (0.09 MB XLS)
Table S8. Univariate cox analysis of clones used in the renal
cell carcinoma study. List of clones obtained using univariate
cox analysis of "stroma up" genes presented in Table S3, mapped
to the renal cell carcinoma data set [21].
Found at: doi:10.1371/journal.pone.0000032.s011 (0.09 MB XLS)
Table S9. List of common genes obtained by cross-study
comparisons between our study ("stroma up" genes) and:
"DTF genes" [27], the "wound-response signature" [28],
and the "fibroblasts/myofibroblasts lists" [30].
Found at: doi:10.1371/journal.pone.0000032 (0.02 MB XLS)
Materials and Methods S1. Supplemental materials and
methods.
Found at: doi:10.1371/journal.pone.0000032.s013 (0.03 MB
DOC)
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